



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/929,666	08/14/2001	Richard W. Anderson	28341/00287A	9424

4743 7590 04/16/2004

MARSHALL, GERSTEIN & BORUN LLP  
6300 SEARS TOWER  
233 S. WACKER DRIVE  
CHICAGO, IL 60606

EXAMINER

KIM, VICKIE Y

ART UNIT PAPER NUMBER

1614

DATE MAILED: 04/16/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

*Supplemental*  
**Notice of Allowability**

Application No.

09/929,666

Examiner

Vickie Kim

Applicant(s)

ANDERSON ET AL.

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to telephonic conversation(interview) on 4/5/04.
2. ☒ The allowed claim(s) is/are 1,3,4 and 13-21.
3. ☐ The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
  6. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
    - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
      - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
    - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4. ☐ Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),  
Paper No./Mail Date 4/14/03.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_.

**VICKIE KIM**  
**PRIMARY EXAMINER**

Vickie Kim  
Primary Examiner  
Art Unit: 1614

### **Supplemental Examiner's Amendment**

1. Acknowledgement is made of applicant's request to correct the inadvertent typographical errors made in previous office action(see communication mailed 3/25/04). The applicant's request is verified and considered to be reasonable. The terms(i.e. hydroxy in line 15, C=S in line 17 and "or" in line 20) in question were missing when the claim 1 is copied from original claim 1. The missing terms should be reinstated without question the validity of patentability of the claims and the patentability should be maintained as valid.

2. This supplemental office action is supercedes any office action previously issued.

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Patel, Sandip on 3/10/04.

4. The application has been amended as follows:

a. Replace the claim 1 with newer amended version as following:

--- Claim 1 (currently amended): A method of treating or suppressing the symptoms of addictive disorders selected from the group consisting of alcohol addiction, tobacco addiction, nicotine addiction, and intoxication and inhalation disorders associated with alcohol, tobacco and nicotine addiction, said method

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-5</sub> alkenyl, C<sub>3-5</sub>

$n$  is 0 or 1;

A is CH, CH<sub>2</sub>, CH-halogen, CHCH<sub>3</sub>, C=O, C=S, C-SCH<sub>3</sub>, C=NH, C-NH<sub>2</sub>,

B is CH<sub>2</sub>, CH, CH-halogen, C=O, N, NH, N-CH<sub>3</sub>, or O;

and pharmaceutically acceptable derivatives or salts of said active agent. ---

Art Unit: 1614

- b. In claim 17, lines 2-3, delete the phrase [selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, and a cabergoline] right before "administered".
- c. In claim 18, lines 2-3, delete the phrase [selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, and a cabergoline] right before "administered".

### ***Conclusion***

- 5. All the pending claims are allowed.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579(fax: 571-273-0579). The examiner can normally be reached on Tuesday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on 571-272-0584. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-746-3165 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Application/Control Number: 09/929,666

Page 5

Art Unit: 1614

**VICKIE KIM**  
**PRIMARY EXAMINER**

Vickie Kim  
April 13, 2004  
Art unit 1614